Healios K.K.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HLOSF research report →
Price Chart
About the company
Healios K. K. is a biotechnology firm specializing in the innovation, development, production, and commercialization of cell therapy and regenerative medicine products, with operations spanning Japan, Europe, and the United States.
- CEO
- Tadahisa S. Kagimoto
- IPO
- 2020
- Employees
- 75
- HQ
- Tokyo, JP
Get TickerSpark's AI analysis on HLOSF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $243.00M
- P/E
- 60.69
- Fwd P/E
- 0.10
- PEG
- 0.20
- P/S
- 688.74
- P/B
- 4.63
- EV/EBITDA
- -13.21
- Div Yield
- 0.00%
- Gross Margin
- -577.97%
- Op Margin
- -7110.17%
- Net Margin
- 349.15%
- ROE
- 3.41%
- ROIC
- -14.76%
Latest fiscal year · YoY change
- Revenue
- $104.09M-81.4%
- Gross Profit
- $-389,339,446-190.1%
- Op Income
- $-3,405,969,498
- Net Income
- $-2,218,934,580+47.6%
- EPS
- $-20.59+57.0%
- OCF Growth
- -74.3%
- FCF Growth
- -57.1%
- 52W High
- $3.63
- 52W Low
- $1.80
- 50D MA
- $1.80
- 200D MA
- $2.02
- Beta
- 1.43
- RSI (14)
- 5
- Avg Volume
- 22
No earnings-call transcripts are available for HLOSF yet.
- Free Float
- 48.2%
- Shares Outstanding
- 135.00M
- Float Shares
- 65.10M
Our HLOSF coverage
Recent articles, reports, and earnings notes.
No research on HLOSF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate HLOSF report →